What is HC Wainwright’s Forecast for Belite Bio Q2 Earnings?

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) – Investment analysts at HC Wainwright cut their Q2 2026 earnings per share (EPS) estimates for shares of Belite Bio in a research note issued on Thursday, May 21st. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.84) for the quarter, down from their previous forecast of ($0.72). HC Wainwright has a “Buy” rating and a $200.00 price objective on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Belite Bio’s Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.87) EPS, FY2026 earnings at ($3.23) EPS and FY2027 earnings at $5.82 EPS.

Several other equities analysts have also recently weighed in on the company. Mizuho set a $223.00 price target on Belite Bio in a report on Thursday, February 19th. Morgan Stanley raised their price target on Belite Bio from $191.00 to $201.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. Needham & Company LLC set a $217.00 price target on Belite Bio in a report on Tuesday, March 3rd. Wall Street Zen upgraded Belite Bio from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Finally, Cantor Fitzgerald raised their price target on Belite Bio from $200.00 to $266.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $203.80.

Belite Bio Price Performance

NASDAQ BLTE opened at $137.30 on Monday. The stock has a market capitalization of $5.49 billion, a PE ratio of -54.27 and a beta of -1.19. The business has a 50 day simple moving average of $159.26 and a two-hundred day simple moving average of $156.92. Belite Bio has a 1-year low of $56.10 and a 1-year high of $200.00.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.26.

Institutional Trading of Belite Bio

A number of institutional investors have recently bought and sold shares of BLTE. Caitong International Asset Management Co. Ltd lifted its stake in shares of Belite Bio by 28,200.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock worth $45,000 after acquiring an additional 282 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Belite Bio by 28.1% during the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock worth $87,000 after acquiring an additional 257 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Belite Bio during the 4th quarter valued at $103,000. Persistent Asset Partners Ltd bought a new stake in Belite Bio during the 4th quarter valued at $108,000. Finally, EverSource Wealth Advisors LLC bought a new stake in Belite Bio during the 2nd quarter valued at $147,000. 0.53% of the stock is currently owned by institutional investors.

Insider Transactions at Belite Bio

In related news, insider Nathan L. Mata sold 666 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $153.21, for a total value of $102,037.86. Following the completion of the sale, the insider directly owned 440 shares in the company, valued at $67,412.40. This trade represents a 60.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 26,166 shares of company stock valued at $4,548,351 in the last ninety days. 13.29% of the stock is owned by company insiders.

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.